lifestyle.dietfitnessforall.com

Author: BRIAN COMMUNICATIONS

GEMMABio Unveils Duchenne Muscular Dystrophy (DMD) Program and Presents Preclinical Data for Next‑Generation Gene Therapies for DMD and Spinal Muscular Atrophy Type 1 (SMA1) at the ASGCT 2026 Annual Meeting

May 14, 2026
GEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221, Investigational Next‑Generation Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)

March 11, 2026
PHILADELPHIA BREAKS GROUND ON TEN-BLOCK TRANSFORMATION IN CENTER CITY

January 14, 2026